hookula has it right. Sez "You should be buying all the shares you can in the next few months..." Also,IMO this board has not deteriorated so much as the news stream from PPHM has closed... concluding a quiet and difficult year indeed. Consolidation. No bad news. Bavituximab has established and enduring safety and has anti-tumor activity. This year we understand better WHY it has efficacy when administered as a "naked" antibody. Now "industry" is check out if they can easily synthesize something a bit more "upstream" in its activity than Bavi. So far the tech is holding up. As far as I know. PPHM continues to explore the appropriate indications for its use while awaiting a white knight to give the company a financial updraft to support Phase III Bavituximab human trials. Let's get on with it. So who is holding the price down? How does a stock hover at this level without support. And why does a product with so much application in cancer treatment stall in development? Or is it stalled? We know Bavi is probably not the best iteration of spin-offs from this technology. Can it be distributed and used in combination with other immuno-stimulants? In an ideal world Bavi would be used simultaneously BOTH as a "contrast medium" (a "dye") for spotting tiny tumors, AND a simultaneous treatment, by whistling in immune cells. Bavi will have best application when tumors are suspected and treated before they become distinctly visible on CT or MRI. Until then, we need more than immunostimulants, and attacks on tumor vasculature. We need directed cytotoxins, and specifically those that can penetrate to the core of medium size and large tumors and kill the dormant cancer cells there that irradiation and chemotherapy cannot reach (read: Cotara).
Who has the money to stabilize the price of a penny stock. Huge numbers of entities: GovernmentS,university interests,large corporations, and, globally, a raft of individuals. Why? If the anti-phospholipid platform is hefty as we think, its development will have a huge effect on mankind. Is that dreaming? I wrote here a couple months ago about meeting the (grand?)mother of monoclonal antibody therapy, forming a new company with an anti-cancer antibody. When I asked her in private after the meeting what she thought of PeregrinePHM Bavituximab she looked at me blankly and said, "I've never heard of it". One take-away is we're in a pretty narrow corridor of pursuit. Hopefully it's not that we're barking up the wrong tree...or alley.
AI
